Roche blindsided by off-label Avastin fallout in India

Emily Wasserman

, maker of pricey wet age-related macular degeneration drug Lucentis, has long railed against countries' moves to use its cancer drug off-label for the same condition, arguing that there isn't any real proof that the med can safely treat the blinding eye disease. Now the company has new ammo to bolster its argument, as two states in suspended sales of Avastin after it caused vision problems in patients.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS